Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-102 in advanced breast cancer
NCT00802945Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Oct 2008
- Primary completion
- Oct 2011
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of etirinotecan pegol in breast cancer, sponsored by Nektar Therapeutics. Started Oct 2008; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00802945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00802945.